What impact does NICE’s modified Cancer Drugs Fund process mean for patient access to new oncology pharmaceuticals in England?
In April 2016, NICE modified the Cancer Drugs Fund (CDF) appraisal process, to review all new oncology indications and publish final guidance within 90 days of marketing authorisation. Additionally, 14 existing legacy treatments from the previous CDF had not undergone a NICE assessment and required review.
Treatments appraised under this process may be recommended for routine use by NHS England; retained in the CDF to gather additional evidence or not recommended. This study investigates the efficiency of the new CDF appraisal process for indications without prior NICE evaluations.
Read our findings here….(NICE Impact of modified CDF on access)